Drug
Spironolactone 100mg
Spironolactone 100mg is a pharmaceutical drug with 6 clinical trials. Historical success rate of 80.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_1
2
33%
Ph phase_2
1
17%
Ph phase_4
2
33%
Phase Distribution
2
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
4 of 6 finished
Non-Completion Rate
33.3%
2 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(4)
Terminated(2)
Detailed Status
Completed4
Terminated1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 4
Trials by Phase
Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 42 (40.0%)
Trials by Status
completed467%
terminated117%
withdrawn117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_1
Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
NCT04283656
completedphase_1
Spironolactone Therapy In Young Women With NASH
NCT03576755
withdrawnphase_4
Spironolactone for Hidradenitis Suppurativa
NCT04100083
completed
Spironolactone in Covid-19 Induced ARDS
NCT04345887
completedphase_2
Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
NCT02585843
Clinical Trials (6)
Showing 6 of 6 trials
NCT04283656Phase 1
Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
NCT03576755Phase 1
Spironolactone Therapy In Young Women With NASH
NCT04100083Phase 4
Spironolactone for Hidradenitis Suppurativa
NCT04345887
Spironolactone in Covid-19 Induced ARDS
NCT02585843Phase 2
Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
NCT01843309Phase 4
Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6